Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy

NCT07807111 is registered in ClinicalTrials.gov with SparingVision as lead sponsor.

NCT NCT07807111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy
Lead sponsor
SparingVision
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 8, 2025
Completion date
March 31, 2032
Enrollment
27 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa (rp), rod cone dystrophy